147 related articles for article (PubMed ID: 25630534)
1. Antiangiogenic ruthenium(ii) benzimidazole complexes, structure-based activation of distinct signaling pathways.
Lai H; Zhao Z; Li L; Zheng W; Chen T
Metallomics; 2015 Mar; 7(3):439-47. PubMed ID: 25630534
[TBL] [Abstract][Full Text] [Related]
2. Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.
Yellol J; Pérez SA; Buceta A; Yellol G; Donaire A; Szumlas P; Bednarski PJ; Makhloufi G; Janiak C; Espinosa A; Ruiz J
J Med Chem; 2015 Sep; 58(18):7310-27. PubMed ID: 26313136
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
4. Interaction between 8-hydroxyquinoline ruthenium(II) complexes and basic fibroblast growth factors (bFGF): inhibiting angiogenesis and tumor growth through ERK and AKT signaling pathways.
Yang L; Zhang J; Wang C; Qin X; Yu Q; Zhou Y; Liu J
Metallomics; 2014 Mar; 6(3):518-31. PubMed ID: 24336978
[TBL] [Abstract][Full Text] [Related]
5. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic Ruthenium(II) Complexes of Pyrazolylbenzimidazole Ligands That Inhibit VEGFR2 Phosphorylation.
Chakraborty A; Roy S; Chakraborty MP; Roy SS; Purkait K; Koley TS; Das R; Acharya M; Mukherjee A
Inorg Chem; 2021 Dec; 60(23):18379-18394. PubMed ID: 34780170
[TBL] [Abstract][Full Text] [Related]
7. The PPARδ ligand L-165041 inhibits VEGF-induced angiogenesis, but the antiangiogenic effect is not related to PPARδ.
Park JH; Lee KS; Lim HJ; Kim H; Kwak HJ; Park HY
J Cell Biochem; 2012 Jun; 113(6):1947-54. PubMed ID: 22234939
[TBL] [Abstract][Full Text] [Related]
8. 12-Deoxyphorbol 13-palmitate inhibit VEGF-induced angiogenesis via suppression of VEGFR-2-signaling pathway.
Xu HY; Pan YM; Chen ZW; Lin Y; Wang LH; Chen YH; Jie TT; Lu YY; Liu JC
J Ethnopharmacol; 2013 Apr; 146(3):724-33. PubMed ID: 23434607
[TBL] [Abstract][Full Text] [Related]
9. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
Chen MC; Lee CF; Huang WH; Chou TC
Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
[TBL] [Abstract][Full Text] [Related]
10. Selenadiazole Derivatives Inhibit Angiogenesis-Mediated Human Breast Tumor Growth by Suppressing the VEGFR2-Mediated ERK and AKT Signaling Pathways.
Lai H; Fu X; Sang C; Hou L; Feng P; Li X; Chen T
Chem Asian J; 2018 Jun; 13(11):1447-1457. PubMed ID: 29575811
[TBL] [Abstract][Full Text] [Related]
11. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
Jung MH; Lee SH; Ahn EM; Lee YM
Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
[TBL] [Abstract][Full Text] [Related]
12. A Macrocyclic Ruthenium(III) Complex Inhibits Angiogenesis with Down-Regulation of Vascular Endothelial Growth Factor Receptor-2 and Suppresses Tumor Growth In Vivo.
Kwong WL; Lam KY; Lok CN; Lai YT; Lee PY; Che CM
Angew Chem Int Ed Engl; 2016 Oct; 55(43):13524-13528. PubMed ID: 27717148
[TBL] [Abstract][Full Text] [Related]
13. Baicalein potently suppresses angiogenesis induced by vascular endothelial growth factor through the p53/Rb signaling pathway leading to G1/S cell cycle arrest.
Ling Y; Chen Y; Chen P; Hui H; Song X; Lu Z; Li C; Lu N; Guo Q
Exp Biol Med (Maywood); 2011 Jul; 236(7):851-8. PubMed ID: 21659383
[TBL] [Abstract][Full Text] [Related]
14. Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway.
Li M; Wu S; Liu Z; Zhang W; Xu J; Wang Y; Liu J; Zhang D; Tian H; Li Y; Ye W
Biochem Pharmacol; 2012 May; 83(9):1251-60. PubMed ID: 22305746
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic activity of mononuclear copper(II) polypyridyl complexes for the treatment of cancers.
Nagababu P; Barui AK; Thulasiram B; Devi CS; Satyanarayana S; Patra CR; Sreedhar B
J Med Chem; 2015 Jul; 58(13):5226-41. PubMed ID: 26068145
[TBL] [Abstract][Full Text] [Related]
16. Rational Design of Ruthenium Complexes Containing 2,6-Bis(benzimidazolyl)pyridine Derivatives with Radiosensitization Activity by Enhancing p53 Activation.
Deng Z; Yu L; Cao W; Zheng W; Chen T
ChemMedChem; 2015 Jun; 10(6):991-8. PubMed ID: 25914192
[TBL] [Abstract][Full Text] [Related]
17. Palladium (II) complex and thalidomide intercept angiogenic signaling via targeting FAK/Src and Erk/Akt/PLCγ dependent autophagy pathways in human umbilical vein endothelial cells.
Aydinlik S; Uvez A; Kiyan HT; Gurel-Gurevin E; Yilmaz VT; Ulukaya E; Armutak EI
Microvasc Res; 2021 Nov; 138():104229. PubMed ID: 34339726
[TBL] [Abstract][Full Text] [Related]
18. The biological effect of the nitroimidazole derivative of a polypyridyl ruthenium complex on cancer and endothelial cells.
Mazuryk O; Suzenet F; Kieda C; Brindell M
Metallomics; 2015 Mar; 7(3):553-66. PubMed ID: 25711770
[TBL] [Abstract][Full Text] [Related]
19. Deltonin inhibits angiogenesis by regulating VEGFR2 and subsequent signaling pathways in endothelial cells.
Tong Q; Zhao Q; Qing Y; Hu X; Jiang L; Wu X
Steroids; 2015 Apr; 96():30-6. PubMed ID: 25554580
[TBL] [Abstract][Full Text] [Related]
20. OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt-NF-κB and MAPK signaling pathways.
Omar HA; Arafa el-SA; Salama SA; Arab HH; Wu CH; Weng JR
Toxicol Appl Pharmacol; 2013 Nov; 272(3):616-24. PubMed ID: 23921148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]